Skip to content
Medical Health Aged Care, Research Development

Renowned specialist breast surgeon to collaborate with research group.

bella PR, on behalf of: Dr Nicole Yap and Fiona Elsey Cancer Research Institute 3 mins read
Dr Nicole Yap, Specialist Breast Surgeon and Professor George Kannourakis, Director of the Fiona Elsey Cancer Research Institute

The Fiona Elsey Cancer Research Institute has announced that renowned Melbourne specialist breast surgeon, Dr Nicole Yap, will work with the Breast cancer research group as a Collaborating Clinician in metropolitan Melbourne. Through this collaboration, Dr Yap will bring her patients perspective to the work and highlight the groups research of to a wider audience.

 

Dr Nicole Yap is a Specialist Breast Surgeon and founding director of Australian Breast Care Centre (ABCC). Dr Yap treats both the cancer and the cosmetic outcome at the same oncoplastic surgery, maintaining or possibly improving the aesthetic/cosmetic outcome. Dr Yap is involved with multiple associations including deputy chair of RACS, AMA councillor, President Chinese Medical Association of Victoria, Vice President of Medical Legal Society Victoria and sits on the board of Pink Hope.

 

Breast cancer is one of the most common cancers in women with one million cases of breast cancer diagnosed around the world each year. Triple-negative breast cancers account for 10%–20% of breast cancers and have been reported to be more aggressive and associated with poorer survival than other subtypes of breast cancers. Notably, the triple-negative subtype of breast cancer is encountered more often in pregnancy and has an aggressive clinical course.

 

The breast cancer researchers at the Fiona Elsey Cancer Research Institute are focused on this aggressive subtype of breast cancer. 

 

In world first work, the group have reported the behaviour and function of a pregnancy associated plasma protein (PAPPA), that is highly found in aggressive triple-negative breast cancers. High PAPPA concentrations are generally detected in blood of pregnant women. However, in breast cancer patients, researchers found that an abnormal overexpression of PAPPA negatively affects survival rates and increases the risk of the cancer recurring. The research sought to understand its functional consequences, and findings revealed that PAPPA plays an important role in regulating key cell motility networks in breast cancers.

 

“As the first Metropolitan based breast surgeon to be accepted as a collaborating clinician, I am honoured to officially support this important research and I encourage other breast cancer surgeons to follow in my footsteps to help bring more patient perspectives and expose the research to a wider audience.” Dr Nicole Yap

 

“I have chosen to donate my resources to the FECRI based on their current studies which align with my charity Australian Breast Care Centre. Triple negative breast cancer is one of the most aggressive breast cancers and tends to be associated with women under the age of 50 and certain genetic mutations.” Said Dr Yap.

 

“We are fortunate to have Dr Yap support of our Breast cancer group. We are grateful for her interest in our work here in Ballarat and look forward to working with her. ”Professor George Kannourakis, Director of the Fiona Elsey Cancer Research Institute

 


Key Facts:

Breast cancer is one of the most common cancers in women with one million cases of breast cancer diagnosed around the world each year. Triple-negative breast cancers account for 10%–20% of breast cancers and have been reported to be more aggressive and associated with poorer survival than other subtypes of breast cancers. Notably, the triple-negative subtype of breast cancer is encountered more often in pregnancy and has an aggressive clinical course.


About us:

For more information on the Fiona Elsey Cancer Reserarch Institute, please visit https://fecri.org.au/

For more information about Dr Nicole Yap, please visit https://www.drnicoleyap.com.au/ or https://www.australianbreastcarecentre.com.au/

 

 


Contact details:

For all media enquiries for Dr Nicole Yap, please contact: bella PRBelinda Visser mb. 0431 27 41 69 e. belinda@bellapr.com.au 

For all media enquiries for Professor George Kannourakis, please contact: Fiona Elsey Cancer Research Institute, Sarah Stapleton mb. 0475 383 687 e. sarah@fecri.org.au

 

Media

More from this category

  • Environment, Medical Health Aged Care
  • 01/12/2023
  • 10:43
West Australian doctors peak bodies

WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health

On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…

  • Medical Health Aged Care
  • 01/12/2023
  • 10:12
Australian Dental Industry Association

ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia

1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 01/12/2023
  • 09:17
Aegros

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.